Levecad 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure activity. This medication is typically prescribed as adjunctive therapy in adults and pediatric patients aged four years and above. Levecad 500 is well-absorbed orally, with rapid onset of action and minimal drug interactions, making it suitable for monotherapy or combination therapy. The dosage should be individualized based on clinical response and tolerability, with gradual titration recommended to minimize adverse effects. Common side effects include dizziness, somnolence, headache, and fatigue, while serious adverse reactions are rare but may involve behavioral changes or hypersensitivity. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Levecad 500 should be used under medical supervision, with regular monitoring to assess efficacy and safety. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any formulation components. Patients are advised to adhere strictly to prescribed dosing and report any unusual symptoms promptly.